Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its target price lifted by Piper Sandler from $128.00 to $131.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 82.59%, which has investors questioning if this is right ...

Learn more about whether Corcept Therapeutics Incorporated or Royalty Pharma plc is a better investment based on AAII's A+ ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.